

Phospholipase A₂ inhibitors from marine algae

Alejandro M.S. Mayer¹, Valerie J. Paul², William Fenical³, James N. Norris⁴, M.S. de Carvalho⁵ & Robert S. Jacobs⁵

¹Louisiana State University Medical Center, Department of Physiology, 1901 Perdido Street, New Orleans, LA 70112-1393, USA; ²University of Guam – Marine Laboratory, UOG Station, Mangilao, Guam 96923, USA; ³Scripps Institution of Oceanography, University of California – San Diego, La Jolla, CA 92093-0236, USA; ⁴Department of Botany, NH B166, National Museum of Natural History, Smithsonian Institution, Washington, D.C. 20560, USA; ⁵Department of Biological Sciences, University of California-Santa Barbara, Santa Barbara, CA 93106, USA

Key words: phospholipase A₂ inhibitors, marine algae, marine secondary metabolites, Rhodophyta, Phaeophyta, Chlorophyta, marine natural products.

Abstract

Twelve out of twenty-nine compounds isolated from benthic marine algae from the phyla Chlorophyta, Phaeophyta and Rhodophyta have been found to be potent inhibitors of bee venom derived phospholipase A₂ (PLA₂) (> 50%) in the μ M range. The compounds investigated were from: *Bryopsis pennata*, *Rhizocephalus phoenix*, *Caulerpa prolifera*, *C. racemosa*, *C. bikinensis*, *Cymopolia barbata*, *Laurencia cf. palisada*, *Laurencia sp.*, *Ochtodes crockeri*, *Liagora farinosa*, *Sphaerococcus coronipifolius*, *Phacelocarpus labillardieri*, *Dictyota sp.*, *Bifurcaria galapagensis*, *Stypopodium zonale*, *Dictyopteris undulata*, *Stoechospermum marginatum*, *Dictyopteris divaricata*, *Dilophus fasciola* and *Dilophus sp.* This is the first report of bee venom PLA₂ inhibition *in vitro* by pure compounds isolated from marine algae.

Introduction

Phospholipases A₂ [PLA₂] are ubiquitous lipolytic cellular enzymes found in all cell types, as well as bacteria and protozoa, that specifically hydrolyze the 2-acyl ester bond of 1,2-diacyl-sn-3 glycerophosphatides. These enzymes play a major role in both phospholipid turnover and the regulatory mechanisms controlling inflammatory responses, since the release of arachidonic acid by PLA₂ and its subsequent metabolism by the cyclooxygenase or the 5-lipoxygenase enzyme systems leads to the synthesis of the bioactive eicosanoids (prostaglandins, thromboxanes and leukotrienes) (Flower & Blackwell, 1976). The

contribution of PLA₂ enzymatic activity to the pathogenesis of human disease has been extensively reviewed (Vadas & Pruzanski, 1986). Enhanced levels of extracellular PLA₂ activity have been observed in septic shock (Vadas *et al.*, 1988), and inflammatory diseases such as pancreatitis, psoriasis and rheumatoid arthritis (Gonzalez-Butirica *et al.*, 1989). After PLA₂ is activated it could mediate pathophysiological processes both by a direct action or indirectly through subsequent transformation of its products, lysophospholipids and arachidonic acid, to eicosanoids (prostaglandins and leukotrienes) and platelet-activating factor (Dennis *et al.*, 1991). These observations provide a strong rationale for the no-

tion that inhibitors of this enzyme could provide novel therapies to alleviate the above mentioned diseases.

At present there is considerable research in developing potent inhibitors of PLA₂ (Mayer *et al.*, 1988) and a number of compounds which represent a diversity of structural types have been reported to inhibit PLA₂ (Chang *et al.*, 1987). These compounds may be broadly described as agents that affect substrate-enzyme interface, agents that modulate cellular calcium levels, non-steroidal anti-inflammatory compounds, natural products, covalent binding agents, substrate or product analogs and compounds derived from screening. Most of these agents are limited in their *in vitro* potency and *in vivo* pharmacological activity (Chang *et al.*, 1987; Glaser & Jacobs, 1986). A few years ago, a survey of the biomedical potential of marine natural products derived from marine invertebrates resulted in the isolation of a novel nonsteroidal sesterterpenoid, manoalide, from the marine sponge *Luffariella variabilis* (deSilva & Scheuer, 1980). Manoalide was subsequently shown to be a potent irreversible inhibitor of bee venom PLA₂ (IC₅₀ = 0.05 μM) (Glaser & Jacobs, 1986; de Freitas *et al.*, 1984) and human synovial fluid PLA₂ (IC₅₀ = 0.2 μM) (Jacobson *et al.*, 1990).

Recently, the anti-inflammatory survey was extended to include pure compounds isolated from selected marine algae belonging to the phyla Chlorophyta, Phaeophyta and Rhodophyta as possible sources of extracellular bee-venom PLA₂ inhibitors.

Materials and methods

Isolation of algal metabolites

A variety of compounds (1-29) isolated from 21 species marine algae were used in this study (Figs 1 and 2). All compounds were isolated and purified by standard methods, and their structures verified by NMR and other spectroscopic methods. Each of the compounds, with the exception of compounds 1, 18, 19 and 24, were isolated and described in prior chemical publications. The fol-

lowing references elucidate and describe the structures of metabolites 1-29: 1: Paul & Fenical (1991, personal communication); 2: Sun & Fenical (1979a); 3: Amico *et al.* (1978); 4: Paul & Fenical (1982); 5-6: Hogberg *et al.* (1976); 7: Paul & Fenical (1980a); 8: Shin *et al.* (1986); 9: Fenical *et al.* (1976); 10: Gerwick *et al.* (1979); 11-12: Fenical *et al.* (1973); 13: Sun & Fenical (1979b); 14: Blackman & Wells (1978); 15-17: Paul & Fenical (1980b); 18-19: Capon *et al.* (1981 a,b); 20: Paul & Fenical (1980c); 21: Shin *et al.* (1986); 22: Sun & Fenical (1979b); 23: Gerwick *et al.* (1979); Gerwick & Fenical (1981b); 24: Fenical (personal communication); 25: Suzuki *et al.* (1981) and Suzuki & Kurosawa (1981); 26: Amico *et al.* (1978); 27: Sun *et al.* (1977); 28: Gerwick *et al.* (1981) and Gerwick & Fenical (1981); 29: Sun *et al.* (1980). See Faulkner *et al.* (1984a-b; 1986; 1987; 1988; 1990) for additional references for isolation of compounds.

Phospholipase A₂ assay

The PLA₂ assay currently used in our laboratory has been previously described in detail (de Freitas *et al.*, 1984; Glaser & Jacobs, 1986). Briefly, mixed micelles of 1.35 mM dipalmitoyl phosphatidylcholine, 2.76 mM Triton X-100, and 0.5 μCi of 2- α -palmitoyl (2-palmitoyl-9,10-³H) phosphatidylcholine (specific activity 57 mCi mmol⁻¹) were prepared in 10 mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid, (HEPES) 1 mM CaCl₂, pH 7.4 at 41 °C. Bee venom phospholipase A₂ (Boehringer Mannheim, W. Germany) (5 μl of a 50 unit ml⁻¹ solution) which had been pre-incubated with a test compound or vehicle (DMSO or MeOH) for 1 hr at 41 °C was added to 0.5 ml of substrate (100-fold dilution of test compound/enzyme complex, final enzyme concentration 1 unit ml⁻¹), incubated for 15 s at 41 °C and extracted as described previously (Glaser & Jacobs, 1986). Released (³H) palmitic acid (heptane phase) was added to 3.0 ml Ecosint (National Diagnostics) and counted in a LKB Rackbeta 1219 liquid scintillation counter. Concentrations of tested compounds are given both as the concentration in the preincubation mixture (μM) as well as the concentration in the assay




Fig. 1. Algal metabolites that showed greater than 50% inhibition of bee venom phospholipase A².

mixture (μM) (Table 1 and 2). The percent inhibition of phosphatidylcholine hydrolysis was determined for each compound, using manoalide ($0.25 \mu\text{M}$) as a control (100% inhibition of PLA₂) in all the experiments.

Results

Tables 1 and 2 show the degree of inhibition of bee venom PLA₂ observed with the 29 compounds tested. All the compounds reported in

Table 1 showed greater than 50% inhibition of bee venom PLA₂. Of these compounds exhibiting active inhibition, 5 were Chlorophyta (*Bryopsis pennata*, *Rhizocephalus phoenix*, *Caulerpa prolifera*, *C. bikinesis* and *Cymplia barbata*), 2 Phaeophyta (*Styopodium zonale* and *Dictyopteris undulata*), and 3 Rhodophyta (*Liagora farinosa*, *Phacelocarpus libillardieri*, and *Sphaerococcus coronipifolius*). Seven compounds showed greater than 90% inhibition of PLA₂ within the μM range: Rhizocephalin (2), a linear sesquiterpenoid from the green alga *Rhizocephalus phoenix* (99% inhi-




Fig. 2. Algal metabolites that showed less than 50% inhibition of bee venom phospholipase A₂.

Table 1. Inhibition of bee venom PLA₂ by algal metabolites: active compounds^a

Species	Compound #	MW ^b	μM^c	μM^d	% inhibition ^e
CHLOROPHYTA					
Bryopsidales					
Udotaceae					
<i>Bryopsis pennata</i> Lamouroux	1	494	320	3.2	64
Codiaceae					
<i>Rhizocephalus phoenix</i> (Ellis et Solander) Kuetzing	2	378	410	4.1	99
Caulerpaceae					
<i>Caulerpa prolifera</i> (Forsskål) Lamouroux	3	374	420	4.2	92
<i>Caulerpa bikiensis</i> W. Taylor	4	320	490	4.9	63
Dasycladales					
Dasycladaceae					
<i>Cymopolia barbata</i> (Linnaeus) Lamouroux	5	335	470	4.7	98
<i>Cymopolia barbata</i> (Linnaeus) Lamouroux	6	462	340	3.4	98
RHODOPHYTA					
Nemaliales					
Liagoraceae					
<i>Liagora farinosa</i> Lamouroux	7	274	570	5.7	100
Gigartinales					
Sphaerococcaceae					
<i>Phacelocarpus labillardieri</i> (Mertens) J. Agardh	8	356	440	4.4	93
<i>Sphaerococcus coronopifolius</i> Stackhouse	9	381	410	4.1	69
PHAEOPHYTA					
Dictyotales					
Dictyotaceae					
<i>Styopodium zonale</i> (Lamouroux) Papenfuss	10	426	370	3.7	100
<i>Dictyopteria undulata</i> Holmes	11	314	500	5	52
<i>Dictyopteria undulata</i> Holmes	12	312	500	5	76

^a. Greater than 50% inhibition of PLA₂. ^b. Molecular weights of compounds assayed. ^c. Concentration of test compound with PLA₂ in the preincubation mixture. ^d. Concentration of compound with substrate in the assay mixture (100-fold dilution of test compound/enzyme complex). ^e. Percent inhibition of hydrolysis of phosphatidylcholine (manoalide at 0.25 μM used as control for 100% inhibition).

bition; 4.1 μM); caulerpenyne (3), a monocyclic sesquiterpenoid from *Caulerpa prolifera* (92% inhibition; 4.2 μM); two prenylated bromohydroquinones, cymopol (5) and cyclocymopol (6) from *Cymopolia barbata* (98% inhibition; 4.7 and 3.4 μM respectively); an acetylene containing fatty acid derivative (7) from *Liagora farinosa* (100% inhibition; 5.7 μM); a macrocyclic enol-ether (8) from *Phacelocarpus labillardieri* (93% inhibition; 4.4 μM); and stypoldione (10), an orthoquinone from *Styopodium zonale* (100% inhibition; 3.7 μM). Those compounds that showed

less than 50% inhibition of bee venom PLA₂ were considered inactive in this investigation (Table 2).

Discussion

Numerous structurally diverse compounds have been shown to inhibit PLA₂ via different mechanisms, but unfortunately most of these are limited in their *in vitro* potency and *in vivo* pharmacological activities (Chang *et al.*, 1987). As a consequence, there is a continued search for new com-

Table 2. Inhibition of bee venom PLA₂ by algal metabolites: inactive compounds^a

Species	Compound #	MW ^b	μM^c	μM^d	% inhibition ^e
CHLOROPHYTA					
Bryopsidales					
Udotaceae					
<i>Rhipocephalus phoenix</i> (Ellis et Solander) Kuetzing	13	248	635	6.3	20
Caulerpaceae					
<i>Caulerpa racemosa</i> (Forsskål) J. Agardh	14	398	390	3.9	26
RHODOPHYTA					
Ceramiales					
Rhodomelaceae					
<i>Laurencia</i> cf. <i>palisada</i> Yamada	15	314	501	5.0	1
<i>Laurencia</i> cf. <i>palisada</i> Yamada	16	378	416	4.1	0
<i>Laurencia</i> cf. <i>palisada</i> Yamada	17	436	361	3.6	6
<i>Laurencia</i> sp.	18	220	716	7.1	27
<i>Laurencia</i> sp.	19	220	716	7.1	10
Gigartinales					
Rhizophyllidaceae					
<i>Ochtodes crockeri</i> Setchell et Gardner	20	168	937	9.4	26
Sphaerococcaceae					
<i>Phacelocarpus labillardieri</i> (Mertens) J. Agardh	21	126	1250	12.50	26
PHAEOPHYTA					
Dictyotales					
Dictyotaceae					
<i>Dictyota</i> sp.	22	306	514	5.1	41
<i>Styopodium zonale</i> (Lamouroux) Papenfuss	23	552	280	2.8	7
<i>Dictyopteris</i> sp.	24	232	678	6.8	29
<i>Dictyopteris divaricata</i> (Okamura) Nagai	25	222	709	7.1	31
<i>Dilophus fasciola</i> (Roth) Howe	26	222	709	7.1	0
<i>Dilophus</i> sp.	27	304	520	5.2	32
<i>Stoechospermum marginatum</i> (C. Agardh) Kuetzing	28	288	550	5.5	10
Fucales					
Cystoseiraceae					
<i>Bifurcaria galapagensis</i> (Piccone et Grunow) Womersley	29	442	356	3.5	35

^a. Less than 50% inhibition of PLA₂. ^b. Molecular weights of compounds assayed. ^c. Concentration of test compound with PLA₂ in the preincubation mixture. ^d. Concentration of compound with substrate in the assay mixture (100-fold dilution of test compound/enzyme complex). ^e. Percent inhibition of hydrolysis of phosphatidylcholine (manoalide at 0.25 μM used as control for 100% inhibition).

pounds, both by screening natural sources and by design and synthesis to discover compounds that could alleviate human diseases in which phospholipases have been implicated (Ripka *et al.*, 1989).

As part of an extensive and systematic survey designed to uncover specific and potent PLA₂ inhibitors from tropical and temperate marine or-

ganisms, several novel PLA₂ inhibitors have been isolated from marine invertebrates (de Freitas *et al.*, 1984; Kernan *et al.*, 1989) and measurable PLA₂ activity was found in an unusual red alga, *Rhodogorgon* (Burgess & Jacobs, in: Norris & Bucher, 1989). We now extend these findings by reporting that marine algae from three divisions produce structurally diverse compounds which

inhibit bee venom PLA₂ (Tables 1 and 2). In all, compounds from 6 species of Chlorophyta representing 4 families, 9 Phaeophyta of 2 families, and 6 Rhodophyta of 3 families were studied. In particular, we have identified 12 compounds which showed greater than 90% inhibition of bee venom PLA₂ in the μ M range. In general, the active compounds are those which have shown bioactivities in several other assays, such as the bisenol ethers 2-4, which are examples of green algal metabolites known to possess antibiotic and cytotoxic effects (Paul & Fenical, 1987; Hay & Fenical, 1988) and the hydroquinones 5, 6 and 11, and the quinones 10 and 12 which are strong fish antifeedants and possess cytotoxic effects (Hay & Fenical, 1988; Hay *et al.*, 1988). Given these observations, it is difficult to understand the weaker activities of metabolites 14, 21 and 29 (see Fig. 2 and Table 2), each of which possess similar functional groups. On the basis of the results obtained, it must be concluded that predicting enzyme inhibition is difficult if not impossible. In *in vitro* testing, enzyme deactivation could occur by numerous mechanisms involving different binding sites and functionalities. Hence, many structural factors could contribute to overall enzyme deactivation. Further research will determine if these compounds inhibit other PLA₂ enzymes, in particular mammalian types, with the same potency, thus providing preliminary evidence of possible *in vivo* pharmacological activity.

In the marine algae, the biosynthesis and distribution of arachidonic acid (Khotimchenko *et al.*, 1991) as well as the production of eicosanoids (Burgess *et al.*, 1991) have been the focus of increased research in recent years. Furthermore, in the Rhodophyta, enzymatic capacity to metabolize polyunsaturated fatty acids in a way analogous to the lipoxygenase pathway in mammalian systems has been recently reported (Bernart & Gerwick, 1988; Burgess & Jacobs, in: Norris & Bucher, 1989). It has also been shown that several of the algal eicosanoids are identical to 12-lipoxygenase products of human metabolism; however, their biological functions in the physiology of the algae are still unknown (Moghaddam *et al.*, 1989). A hypothesis has re-

cently been proposed that eicosanoids may play a role in the osmoregulation, fertilization, growth and tissue development in marine algae (Gerwick *et al.*, 1990). However, in marine invertebrates, the eicosanoids have been shown to mediate a number of biologically important functions such as regulation of ion flux, hatching, reproduction and cell aggregation (Mayer & Jacobs, 1988). Thus, at this, time proposing a physiological role for compounds that inhibit PLA₂ in marine algae must await further research on the biological role of eicosanoids and other bioactive fatty acids in this life form.

Acknowledgements

This work was supported in part by National Oceanic and Atmospheric Administration, National Sea Grant College Program, Department of Commerce under Grant NA80AA-C-00140, project #s R/MP-21 to (RSJ) and R/MP-39 and -48 (to WF) through the California Sea Grant Program, and in part by the California State Resources Agency. The U.S. Government is authorized to reproduce this paper and distribute it for governmental purposes.

References

- Amico, V., G. Oriente, M. Piattelli, C. Tringali, E. Fattorusso, S. Magno & L. Mayol, 1978. Caulerpenyne, an unusual sesquiterpenoid from the green alga *Caulerpa prolifera*. *Tetrahedron Lett.* 38: 3593-3596.
- Blackman, A. J. & R. J. Wells, 1978. Flexilin and trifarlin, terpene 1,4-diacetoxybuta-1,3-dienes from two *Caulerpa* species (Chlorophyta). *Tetrahedron Lett.* 33: 3063-3064.
- Burgess, J. R., R. I. de la Rosa, R. S. Jacobs & A. Butler, 1991. A new eicosapentaenoic acid formed from arachidonic acid in the coralline red alga *Bossiella orbigniana*. *Lipids* 26: 162-165.
- Capon, R. J., E. L. Ghisalberti & P. R. Jefferies, 1981a. Isoprenoid dihydroquinones from a brown alga, *Cystophora sp.* *Phytochem.* 20: 2598-2600.
- Capon, R. J., E. L. Ghisalberti & P. R. Jefferies, 1981b. New sesquiterpenes from *Caulerpa flexilis* var. *muelleri*. *Aust. J. Chem.* 34: 1775-8.
- Chang, J., J. H. Musser & H. McGregor, 1987. Phospholipase A₂: Function and pharmacological regulation. *Biochem. Pharmacol.* 36: 2429-2436.

- De Freitas, J. C., L. A. Blankemeier & R. S. Jacobs, 1984. *In vitro* inactivation of the neurotoxic action of β -bungarotoxin by the marine natural product, manoalide. *Experientia* 40: 864-865.
- De Silva, E. D. & P. J. Scheuer, 1980. Manoalide, an antibiotic sesterterpenoid from the marine sponge *Luffariella variabilis*. *Tetrahedron* 21: 1611-1614.
- Dennis, E. A., S. G. Rhee, M. M. Billah & Y. A. Hannun, 1991. Role of phospholipases in generating lipid second messengers in signal transduction. *FASEB J.* 5: 2068-2077.
- Faulkner, D. J., 1984a. Marine natural products: metabolites of marine invertebrates. *Nat. Prod. Rep.* 1: 551-598.
- Faulkner, D. J., 1984b. Marine natural products: metabolites of marine algae and herbivorous marine molluscs. *Nat. Prod. Rep.* 1: 251-280.
- Faulkner, D. J., 1986. Marine natural products. *Nat. Prod. Reports.* 3: 1-33.
- Faulkner, D. J., 1987. Marine natural products. *Nat. Prod. Rep.* 4: 539-576.
- Faulkner, D. J., 1988. Marine Natural products. *Nat. Prod. Rep.* 5: 613-663.
- Faulkner, D. J., 1990. Marine natural products. *Nat. Prod. Rep.* 7: 269-309.
- Fenical, W., J. J. Sims, D. Squatrito, R. M. Wing & P. Radlick, 1973. Zonarol and isozonarol, fungitoxic hydroquinones from the brown seaweed *Dictyopteris zonarioides*. *J. Org. Chem.* 38: 2383-2386.
- Fenical, W., J. Finer & J. Clardy, 1976. Sphaerococcenol A; a new rearranged bromoditerpene from the red alga *Sphaerococcus coronopifolius*. *Tetrahedron Lett.* 10: 731-734.
- Flower, R. J. & G. J. Blackwell, 1976. The importance of phospholipase A₂ in prostaglandin biosynthesis. *Biochem. Pharmacol.* 25: 285-291.
- Gerwick, W. H., W. Fenical, N. Fritsch & J. Clardy, 1979. Stypotriol and Stypoldione; Ichthyotoxins of mixed biogenesis from the marine alga *Styopodium zonale*. *Tetrahedron Lett.* 2: 145-148.
- Gerwick, W. H. & W. Fenical, 1981. Ichthyotoxic and cytotoxic metabolites of the tropical brown alga *Styopodium zonale* (Lamouroux) Papenfuss. *J. Org. Chem.* 46: 22-27.
- Gerwick, W. H., W. Fenical & M. U. S. Sultanbawa, 1981. Spatane diterpenoids from the tropical marine alga *Stoehospermum marginatum* (Dictyotaceae). *J. Org. Chem.* 46: 2233-2241.
- Gerwick, W. H., M. W. Bernart, M. F. Moghaddam, Z. D. Jiang, M. L. Solem & D. G. Nagle, 1990. Eicosanoids from the Rhodophyta: new metabolism in the algae. *Hydrobiologia* 204: 621-628.
- Glaser, K. B. & R. S. Jacobs, 1986. Molecular pharmacology of Manoalide. Inactivation of bee venom phospholipase A₂. *Biochem. Pharmacol.* 35: 449-453.
- Gonzalez-Buritica, H., D. M. Smith & R. A. Turner, 1989. Characterization of soluble and cell associated phospholipase A₂ from rheumatoid synovial fluid. *Annu. Rheum. Dis.* 48: 557-564.
- Hay, M. E. & W. Fenical, 1988. Marine plant-herbivore interactions: the ecology of chemical defense. *Annu. Rev. Ecol. Syst.* 19: 111-45.
- Hay, M. E., J. E. Duffy, & W. Fenical, 1988. Seaweed chemical defenses: among-compound and among-herbivore variance. *Proceedings 6th Int. Coral Reef Symp* 3: 43-48.
- Hogberg, H. E., R. H. Thomson & T. J. King, 1976. The cymopols, a group of prenylated bromohydroquinones from the green calcareous alga *Cymopolia barbata*. *J. Chem. Soc. Perkin. Trans. I:* 1696-1701.
- Jacobson, P. B., L. A. Marshall, A. Sung & R. S. Jacobs, 1990. Inactivation of human synovial fluid phospholipase A₂ by the marine natural product, manoalide. *Biochem. Pharmacol.* 39: 1557-1564.
- Kernan, M. R., D. J. Faulkner, L. Parkanyi, J. Clardy, M. S. de Carvalho & R. S. Jacobs, 1989. Luffolide, a novel anti-inflammatory terpene from the sponge *Luffariella sp.* *Experientia* 45: 388-390.
- Khotimchenko, S. V., V. E. Vaskovsky & V. F. Przhemenetskaya, 1991. Distribution of eicosapentaenoic and arachidonic acids in different species of *Gracilaria*. *Phytochemistry* 30: 207-209.
- Mayer, A. M. S. & R. S. Jacobs, 1988. Manoalide: an anti-inflammatory and analgesic marine natural product. In D. G. Fautin (ed.), *Biomedical importance of marine organisms*. California Academy of Sciences, San Francisco: 133-142.
- Mayer, A. M. S., K. B. Glaser & R. S. Jacobs, 1988. Regulation of eicosanoid biosynthesis *in vitro* and *in vivo* by the marine natural product *manoalide*: A potent inactivator of venom phospholipases. *J. Pharmacol. Exp. Ther.* 244: 871-878.
- Moghaddam, M. F., W. H. Gerwick & D. L. Ballantine, 1989. Discovery of 12-(S)-hydroxy-5,8,10,14-icosatetraenoic acid [12-(S)-HETE] in the tropical red alga *Platysiphonia miniata*. *Prostaglandins* 37: 303-308.
- Norris, J. N. & K. E. Bucher, 1989. Rhodogorgon, an anomalous new red algal genus from the caribbean sea. *Proc. Biol. Soc. Wash.* 102: 1050-1066.
- Paul, V. J. & W. Fenical, 1980a. Toxic acetylene-containing lipids from the red alga *Liagora farinosa* Lamouroux. *Tetrahedron Lett.* 21: 3327-3330.
- Paul, V. J. & W. Fenical, 1980b. Palisadins A,B and related monocyclofarnesol-derived sesquiterpenoids from the red marine alga *Laurencia cf. palisada*. *Tetrahedron Lett.* 21: 2787-2790.
- Paul, V. J., O. J. McConnell & W. Fenical, 1980c. Cyclic monoterpenoid feeding deterrents from the red marine alga *Ochtodes crockeri*. *J. Org. Chem.* 45: 3401-3407.
- Paul, V. J. & W. Fenical, 1982. Toxic feeding deterrents from the tropical marine alga *Caulerpa bikiniensis* (Chlorophyta). *Tetrahedron Lett.* 23: 5017-5020.
- Paul, V. J. & W. Fenical, 1987. Natural products chemistry and chemical defense in tropical marine algae of the phylum Chlorophyta. In Paul J. Scheuer (ed.), *Biorganic marine chemistry*, 1. Springer-Verlag, New York: 1-29.

- Ripka, W. C., W. J. Sipio & W. G. Galbraith, 1989. Molecular modelling in the design of phospholipase A₂ inhibitors. *J. Cell Biochem.* 40: 279-286.
- Shin, J., V. J. Paul & W. Fenical, 1986. New macrocyclic α - and γ -pyrones from the marine red alga *Phacelocarpus labillardieri*. *Tetrahedron Lett.* 27: 5189-5192.
- Sun, H. H., S. M. Waraszkiewicz, K. L. Erickson, J. Finer & J. Clardy, 1977. Dictyoxepin and Dictyolene, two new diterpenes from the marine alga *Dictyota acutiloba* (Phaeophyta). *J. Am. Chem. Soc.* 99: 3516-3517.
- Sun, H. H. & W. Fenical, 1979a. Rhipocephalin and rhipocephenal; toxic feeding deterrents from the tropical marine alga *Rhipocephalus phoenix*. *Tetrahedron Lett.* 8: 685-688.
- Sun, H. H. & W. Fenical, 1979b. Hydroxdilophol, a new monocyclic diterpenoid from the brown alga *Dictyota masonii*. *J. Org. Chem.* 44: 1354-1356.
- Sun, H. H., N. M. Ferrara, O. J. McConnell & W. Fenical, 1980. Bifurcarenone, an inhibitor of mitotic cell division from the brown alga *Bifurcaria galapagensis*. *Tetrahedron Lett.* 21: 3123-3126.
- Suzuki, T. & E. Kurosawa, 1981. Okamurallene, a novel halogenated C₁₅ metabolite from the red alga *Laurencia okamurai* Yamada. *Tetrahedron Lett.* 22: 3853-3856.
- Suzuki, T., A. Furusaki, H. Kikuchi, E. Kurosawa & C. Katayama, 1981. The absolute configuration of cycloendosmol from the red alga *Laurencia nipponica* Yamada. *Tetrahedron Lett.* 22: 3423-3426.
- Vadas, P. & W. Pruzanski, 1986. Biology of disease. Role of secretory phospholipases A₂ in the pathobiology of disease. *Lab. Invest.* 55: 391-404.
- Vadas, P., W. Pruzanski, E. Stefanski, B. Sternby, R. Mustard, J. Bohnen, I. Fraser, V. Farewell & C. Bombardier, 1988. Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A₂ levels with circulating collapse. *Crit. Care Med.* 16: 1-7.